[ad_1] The biopharma company’s vacincaptad pegol intravitreal solution is formulated for the treatment of geographic atrophy (GA). Image credit: ©Viacheslav Yakobchuk – stock.adobe.com On Friday, Astellas Pharma Inc. and its…
Tag: Iveric
Iveric Bio Receives U.S. FDA Approval for IZERVAY™ (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy
[ad_1] IZERVAY is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two Phase 3 clinical trials…
Recon: FDA declines to approve Ascendis’ hypoparathyroidism drug; Astellas to buy Iveric for $5.9B
[ad_1] Recon | 01 May 2023 | By Joanne S. Eglovitch Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. In Focus: US FDA advisory committee votes against plan…
Japan’s Astellas to buy US biotech group Iveric Bio for $5.9bn
[ad_1] Astellas Pharma has agreed to buy US biotech group Iveric Bio for roughly $5.9bn, marking the Japanese drugmaker’s largest-ever acquisition and giving it access to the rapidly expanding market…
Astellas Pharma to Buy Iveric Bio for About $5.9B
[ad_1] The Japanese drugmaker said it agreed to acquire Iveric bio for about $5.9 billion to strengthen its capabilities in the ophthalmology field. [ad_2] Source link
Astellas Enters into Definitive Agreement to Acquire Iveric Bio
[ad_1] -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023– -Acquisition advances Astellas’ Primary…